AP2006003650A0 - Sustained release torsemide dosage forms - Google Patents

Sustained release torsemide dosage forms

Info

Publication number
AP2006003650A0
AP2006003650A0 AP2006003650A AP2006003650A AP2006003650A0 AP 2006003650 A0 AP2006003650 A0 AP 2006003650A0 AP 2006003650 A AP2006003650 A AP 2006003650A AP 2006003650 A AP2006003650 A AP 2006003650A AP 2006003650 A0 AP2006003650 A0 AP 2006003650A0
Authority
AP
ARIPO
Prior art keywords
dosage forms
sustained release
torsemide
release torsemide
sustained
Prior art date
Application number
AP2006003650A
Other languages
English (en)
Inventor
Pradeep Sanghvi
Thomas Sciascia
Sara Ketsela
Original Assignee
Penwest Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penwest Pharmaceuticals Co filed Critical Penwest Pharmaceuticals Co
Publication of AP2006003650A0 publication Critical patent/AP2006003650A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AP2006003650A 2003-12-12 2004-12-10 Sustained release torsemide dosage forms AP2006003650A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52913803P 2003-12-12 2003-12-12
PCT/US2004/041963 WO2005058286A1 (en) 2003-12-12 2004-12-10 Sustained release torsemide dosage forms

Publications (1)

Publication Number Publication Date
AP2006003650A0 true AP2006003650A0 (en) 2006-06-30

Family

ID=34699943

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2006003650A AP2006003650A0 (en) 2003-12-12 2004-12-10 Sustained release torsemide dosage forms

Country Status (13)

Country Link
US (1) US20050169991A1 (pt)
EP (1) EP1691790A1 (pt)
JP (1) JP2007513975A (pt)
KR (1) KR20060103330A (pt)
CN (1) CN1929823A (pt)
AP (1) AP2006003650A0 (pt)
AU (1) AU2004299077A1 (pt)
BR (1) BRPI0417123A (pt)
CA (1) CA2548387A1 (pt)
EA (1) EA200600953A1 (pt)
IL (1) IL176222A0 (pt)
MX (1) MXPA06006677A (pt)
WO (1) WO2005058286A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2244324B1 (es) 2004-03-25 2006-11-16 Ferrer Internacional, S.A. Composiciones diureticas de liberacion prolongada.
EP1838273A4 (en) * 2005-01-10 2013-02-20 Elc Man Llc DISCONTINUOUS SURFACE COATING FOR PARTICLES
US7795316B1 (en) * 2007-12-19 2010-09-14 Alcon Research, Ltd. Topical ophthalmic compositions containing tobramycin and dexamethasone
EP2326316A1 (en) * 2008-08-07 2011-06-01 Avantor Performance Materials, Inc. Sustained release compositions comprising gums and sugar alcohols
EP2555756B1 (en) * 2010-04-07 2018-08-22 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
US20140212488A1 (en) * 2012-05-01 2014-07-31 Althera Life Sciences Llc Oral tablet formulation consisting of immediate release rosuvastatin and extended release metformin
US10463622B2 (en) * 2013-10-06 2019-11-05 Sarfez Pharmaceuticals, Inc. Treatments and formulations comprising Torsemide
WO2015050570A1 (en) * 2013-10-06 2015-04-09 Shah Salim Controlled-release formulations comprising torsemide
CN106038500A (zh) * 2016-05-26 2016-10-26 南京正科医药股份有限公司 一种托拉塞米片
US20180125840A1 (en) * 2016-10-25 2018-05-10 Trevi Therapeutics, Inc. Treatment of prurigo nodularis
JP7390695B2 (ja) * 2017-02-03 2023-12-04 株式会社東洋新薬 錠剤及び錠剤の製造方法
JP6893687B2 (ja) * 2017-06-20 2021-06-23 トーアエイヨー株式会社 口腔内崩壊錠
CA3166928A1 (en) 2020-01-10 2021-07-15 Trevi Therapeutics, Inc. Methods of administering nalbuphine
CN113750068A (zh) * 2021-10-28 2021-12-07 江苏睿实生物科技有限公司 一种托拉塞米片及其制备方法
CN116421572A (zh) * 2023-04-28 2023-07-14 黑龙江中医药大学 一种水飞蓟素固体分散体缓释片及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US6569456B2 (en) * 2000-01-13 2003-05-27 Osmotica Corp. Osmotic device containing diltiazem and an ACE inhibitor or diuretic
US6710086B1 (en) * 2000-02-25 2004-03-23 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
US6761895B2 (en) * 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
RU2325152C2 (ru) * 2001-07-04 2008-05-27 Сан Фармасьютикл Индастриз Лимитид Удерживаемая в желудке система регулируемой доставки лекарственного средства
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
JP2005530719A (ja) * 2002-03-29 2005-10-13 ニューロジェン コーポレーション 病原性炎症要素を有する状態の治療のための組み合わせ療法
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs

Also Published As

Publication number Publication date
BRPI0417123A (pt) 2007-08-21
MXPA06006677A (es) 2006-08-31
CA2548387A1 (en) 2005-06-30
WO2005058286A1 (en) 2005-06-30
KR20060103330A (ko) 2006-09-28
AU2004299077A1 (en) 2005-06-30
JP2007513975A (ja) 2007-05-31
EA200600953A1 (ru) 2006-10-27
US20050169991A1 (en) 2005-08-04
CN1929823A (zh) 2007-03-14
IL176222A0 (en) 2006-10-05
EP1691790A1 (en) 2006-08-23

Similar Documents

Publication Publication Date Title
EG27104A (en) Pharmaceutical compounds
IL174343A0 (en) Delayed released dosage forms
AU2003260803A8 (en) Sustained release pharmaceutical composition
AU153930S (en) Tablet
IL176222A0 (en) Sustained release torsemide dosage forms
GB0427455D0 (en) Dosage forms
GB0423964D0 (en) Dosage form
IL163887A0 (en) Controlled release dosage forms
GB0419192D0 (en) Therapeutic agents
GB0316889D0 (en) Pharmaceutical agents
GB0423800D0 (en) New pharmaceutical formulations
GB0308968D0 (en) Medicaments
GB0314733D0 (en) Medicaments
GB0413818D0 (en) Dosage unit
GB2401043B (en) Drug
GB0406048D0 (en) Drug formulations
GB0402491D0 (en) Medicaments
GB0403733D0 (en) Medicaments
ZA200605666B (en) Solid dosage form
GB0403554D0 (en) Improved fire extinguisger
GB0315019D0 (en) Dosage form
EP1624073A4 (en) DRUG
AU158136S (en) Tablet
AU155103S (en) Tablet
GB0329859D0 (en) Medicaments